Evidence map›Paper›PMID 35285177›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Acid-Responsive Dual-Targeted Nanoparticles Encapsulated Aspirin Rescue the Immune Activation and Phenotype in Autism Spectrum Disorder.

Xueqin He, Jiang Xie, Jing Zhang, Xiaorong Wang, Xufeng Jia, Heng Yin, Zhongqing Qiu, Zhihang Yang, Jiao Chen, Zhiliang Ji and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. The blood-brain barrier: a help and a hindrance.Brain : a journal of neurology · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Xueqin HeKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Jiang XieKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Jing ZhangKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Xiaorong WangKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Xufeng JiaKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Heng YinKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Zhongqing QiuKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Zhihang YangKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Jiao ChenState Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
Zhiliang JiState Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen, 361102, China.
Wenqi YuKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Meiwan ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China.
Wenming XuKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.
Huile GaoKey Laboratory of Drug-Targeting and Drug Delivery of MOE, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China.ORCID 0000-0002-5355-7238
Sichuan University · CNXiamen University · CNUniversity of Macau · MO

Funding

111 Project B18035Chengdu Science and Technology Project 2019-YF05-00498-SNNational Natural Science Foundation of China 81872806Science and Technology Plan Project of Sichuan Province 2021YJ0170
6 · The paper itself

Abstract

The treatment of autism spectrum disorder (ASD) is one of the most difficult challenges in neurodevelopmental diseases, because of the unclear pathogenesis research and low brain-lesion targeting efficiency. Besides, maternal immune activation has been reported as the most mature and widely used model of ASD and aspirin-triggered lipoxin A4 is a potent anti-inflammatory mediator being involved in the resolution of neuroinflammation in ASD. Therefore, an aspirin encapsulated cascade drug delivery system (Asp@TMNPs) is established, which can successively target the blood-brain barrier (BBB) and microglial cells and response to the acid microenvironment in lysosome. As a result, the mitochondrial oxidative stress, DNA damage, and inflammation of microglial cells are prominently alleviated. After the treatment of Asp@TMNPs, the social interaction, stereotype behavior, and anxious condition of ASD mice are notably improved and the activation of microglial cells is inhibited. Overall, this system successively penetrates the BBB and targets microglial cells, therefore, it significantly enhances the intracephalic drug accumulation and improves anti-neuroinflammatory efficacy of aspirin, providing a promising strategy for ASD treatment.

Indexed as

Autism Spectrum DisorderNanoparticlesAnimalsAspirinMiceMicrogliaPhenotypeAspirinaspirinautism spectrum disordernanoparticlesneuro-inflammation

Identifiers

PMID35285177
PMCPMC9108608
OpenAlexW4221133084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.